Pseudoephedrine for Clitoral Priapism

Evidence Base and Efficacy

Oral pseudoephedrine 60 mg was only mildly more effective than placebo (28% vs 12%) in treating male prolonged erections following intracavernosal injection, without reaching statistical significance, according to the American Urological Association 1, 2, 3, 4
The 2022 AUA/SMSNA guidelines note that oral therapies including pseudoephedrine demonstrated "modest or inconsistent responses" in randomized controlled studies, indicating a weak evidence base for its use in clitoral priapism 1

Pseudoephedrine should never delay more definitive interventions if the condition persists or worsens, as stated by the American Urological Association 1, 2

Pseudoephedrine works through alpha-adrenergic receptor stimulation to promote vasoconstriction, but its systemic absorption limits targeted clitoral effects 5

Intracavernosal phenylephrine injection is the gold standard for penile priapism, though not well-documented for clitoral priapism, and is preferred over pseudoephedrine due to its alpha-1 selective action without indirect neurotransmitter release, minimizing cardiovascular side effects, as recommended by the American Urological Association 6, 1, 7

Monitor for cardiovascular side effects during pseudoephedrine therapy, including hypertension, tachycardia, and palpitations, which are possible with sympathomimetic agents, according to the American Urological Association 6, 8
These risks are lower with oral pseudoephedrine than with intracavernosal phenylephrine, but still warrant monitoring in patients with cardiovascular disease, as noted by the American College of Cardiology 5